SOURCE: Brighton Markets

May 17, 2012 09:00 ET

2012 Economic Outlook - Report Highlights Acorda Therapeutics Inc and Pharmacyclics, Inc.

HONG KONG--(Marketwire - May 17, 2012) - Today, www.BrightonMarkets.com announced new reports highlighting Acorda Therapeutics Inc (NASDAQ: ACOR) and Pharmacyclics, Inc. (NASDAQ: PCYC). Gain market insight with full analysis and research downloads available at www.BrightonMarkets.com/index.php?coa=ACOR&cob=PCYC.

Economic fundamentals leading into 2012 have set a generally positive pace with GDP growth likely to pick up through the coming year. However, there are several important caveats to note as the world economy continues to face headwinds and risks weigh to the downside. Positive outlooks are conditional on fiscal policy in payroll taxes and unemployment insurance benefits and upon the easing of the European debt situation. A repeat of volatility experience in 2011 is likely in 2012, as perceptions about the strength of the U.S. economy and the euro zone will vary over time as events unfold.

Despite the current situation, our team continues to identify high momentum situations with growth potential -- there remains strong opportunity within careful discretion.

Brighton Markets is releasing new coverage on Acorda Therapeutics Inc for its current position within the healthcare industry. Acorda Therapeutics, Inc. (Acorda) is a commercial-stage biopharmaceutical company. The Company is engaged in the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI), and other disorders of the nervous system. The full research report on Acorda Therapeutics Inc (NASDAQ: ACOR) is available here: www.BrightonMarkets.com/index.php?coa=ACOR.

Brighton Markets has released research on Pharmacyclics, Inc. for its changing role within the healthcare industry. Pharmacyclics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. The Company's clinical development and product candidates are small-molecule enzyme inhibitors designed to target biochemical pathways involved in human diseases. The full research report on Pharmacyclics, Inc. (NASDAQ: PCYC) is available here: www.BrightonMarkets.com/index.php?cob=PCYC.

About Brighton Markets
Brighton Markets was founded on the guiding principle of providing highly relevant, meaningful, and actionable information direct to investors. Across the investment spectrum, Brighton Markets shines light on today's events.

Contact Information